These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thyroid remnant estimation by Tc-99m-sestamibi scanning predicts the effectiveness of rhTSH-stimulated I-131 ablation in patients with differentiated thyroid carcinoma.
    Author: Giovanella L, Suriano S, Castellani M, Ceriani L, Verburg FA.
    Journal: Clin Nucl Med; 2011 Sep; 36(9):781-5. PubMed ID: 21825849.
    Abstract:
    AIM: To evaluate the relationship between postsurgical cervical Tc-99m-sestamibi scan uptake and the rate of successful remnant ablation after recombinant human-thyrotropin (rhTSH)-aided-I-131 ablation in patients with differentiated thyroid carcinoma (DTC). METHODS: In all, 154 DTC patients who underwent total thyroidectomy and rhTSH-aided remnant ablation with I-131 (3.7 GBq) were enrolled. Tc-99m-sestamibi scans were performed during continuing thyroid hormone administration in all cases. Thyroid ablation was assessed after 6 to 12 months by rhTSH-stimulated I-131-whole-body scan and thyroglobulin measurement. The rate of successful ablation, occurrence of radioiodine-induced thyroiditis, and length of hospitalization were correlated with the Tc-99m-sestamibi scintigraphy results. RESULTS: Tc-99m-sestamibi uptake was significantly lower in ablated versus nonablated patients (P<0.0001). A visually positive scan and a Tc-99m-sestamibi uptake greater than 0.9% predicted a high-risk of unsuccessful ablation, prolonged hospitalization, and the occurrence of radioiodine-induced thyroiditis. CONCLUSIONS: Tc-99m-sestamibi scintigraphy is a simple and feasible tool to evaluate thyroid remnants and to predict radioiodine ablation results in patients with DTC.
    [Abstract] [Full Text] [Related] [New Search]